Dr. Jens Vogel-Claussen says the PLCOm2012 model, which includes family history and other factors, detected 97% of lung cancer cases compared to a 77% detection rate with NELSON criteria. Read more
Analyses by Drs. Matthew P. Smeltzer and Raymond U. Osarogiagbon show nodule and LDCT lung cancer screening programs may be serving two distinct populations with only moderate overlap. Read more
During ACLC 2022, Dr. Gee-Chen Chang made the case for moving beyond smoking history to identify at-risk patients and shared an alternative risk predication model that compared favorably against NLST and NELSON. Read more
Prof. Denis Horgan, executive director for the European Alliance for Personalised Medicine, writes that while the intentions behind the EU’s new cancer screening recommendations are laudable, they lack a roadmap for turning ideas into reality. Read more
Aumolertinib may ultimately prove to be an alternative to osimertinib, but it faces challenges before it can win us fda approval. Read more
Evidence demonstrates superior performance of the PLCOm2012 model for identifying individuals for lung cancer screening. Read more
Association aims to bring attention to the often-overlooked links between air pollution and lung cancer. Read more
Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more
Lung cancer specialists are slowly being faced with the challenge of how to balance the benefits of next-generation tumor tissue testing against those of liquid biopsy in the clinic. During […] Read more
Data suggest lung cancer risk scores are not aligned with lung cancer diagnoses in Black patients. Take a closer look at how race influences lung cancer screening. Read more